title: Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
abstract: Type 2 diabetes mellitus continues to be a challenging disease to manage successfully. Beyond the first-line option metformin, there are a number of classes of medications from which to select. This article reviews the new sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin, including their benefits, adverse effects, and potential place in therapy. Upon review, the use of these medications has led to an A1c reduction between -0.37% and -1.16%. These medications also have been shown to reduce A1c when used with insulin. Some adverse effects were noted when using canagliflozin and dapagliflozin, with the most frequent being urinary tract infections and genital mycotic infections. We review the sodium-glucose cotransporter 2 inhibitors approved by the US Food and Drug Administration and their potential roles in the management of type 2 diabetes mellitus.
authors: From the University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville.
authors: Jason
authors: J
authors: Powell
authors: From the University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville.
authors: Shannon A
authors: SA
authors: Miller
authors: From the University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville.
authors: James R
authors: JR
authors: Taylor
mesh_terms: D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000068896:Canagliflozin; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005260:Female; D005960:Glucosides / Q000008:administration & dosage* / Q000009:adverse effects; D006442:Glycated Hemoglobin / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D000068896:Canagliflozin; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; C089180:SLC5A2 protein, human; C529054:dapagliflozin